☰

Charles Lu - Publications

Affiliations: 
Princeton University, Princeton, NJ 
Area:
genomics
Tree Info Grants Similar researchers PubMed Report error

182 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, et al. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. Jama Oncology. PMID 32761153 DOI: 10.1001/Jamaoncol.2020.3362  0.308
2020 Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, ... ... Lu C, et al. Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32389639 DOI: 10.1016/J.Jtho.2020.04.026  0.307
2020 Cascone T, Sepesi B, Lin H, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella F, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, et al. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32193228 DOI: 10.1158/1078-0432.Ccr-19-4180  0.381
2019 Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, et al. Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31778797 DOI: 10.1016/J.Jtho.2019.10.024  0.397
2019 Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900269. PMID 31386610 DOI: 10.1200/Jco.19.00269  0.304
2019 Wang JR, Zafereo M, Dadu R, Ferrarotto R, Busaidy N, Lu C, Ahmed S, Gule-Monroe M, Williams MD, Sturgis E, Goepfert RP, Gross ND, Lai SY, Gunn B, Phan J, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid : Official Journal of the American Thyroid Association. PMID 31319771 DOI: 10.1089/Thy.2019.0133  0.319
2019 Gunn GB, Mendoza TR, Garden AS, Wang XS, Shi Q, Morrison WH, Frank SJ, Phan J, Fuller CD, Chambers MS, Hanna EY, Lu C, Rosenthal DI, Cleeland CS. Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 31037378 DOI: 10.1007/S00520-019-04791-4  0.355
2019 Cabanillas M, Busaidy N, Dadu R, Ferrarotto R, Gross N, Gule-Monroe M, Lu C, Grosu H, Williams M, Zafereo M. OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility Journal of the Endocrine Society. 3. DOI: 10.1210/Js.2019-Or27-6  0.304
2019 Le X, Pickering CR, Rubin ML, Netto F, Kies MS, Johnson FM, Lu C, Blumenschein GR, Bell D, Ginsberg LE, Wilson KF, Lewis J, Feng L, Wang J, Lee JJ, et al. Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection. Journal of Clinical Oncology. 37: 6067-6067. DOI: 10.1200/Jco.2019.37.15_Suppl.6067  0.373
2019 Gao Y, Lu C, Chen H, Wang Z, Wang B, Zhang X, Xu C, Wu Y, Yang J. P1.01-104 Survivals in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer Treated with First-Line Crizotinib Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.819  0.4
2019 Sepesi B, Cascone T, William W, Lin H, Leung C, Weissferdt A, Walsh G, Rice D, Roth J, Mehran R, Hofstetter W, Antonoff M, Fossella F, Mott F, Le X, ... ... Lu C, et al. OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study Journal of Thoracic Oncology. 14: S241-S242. DOI: 10.1016/J.Jtho.2019.08.481  0.375
2019 Moningi S, Nguyen QN, Lin SH, Jeter MD, O'Reilly MS, Chang JY, Chen AB, Allen PK, Lu C, Tsao A, Mohan R, Liao Z. Phase II Trial of Intensity-Modulated Photon or Scanning Beam Proton Therapy Both with Simultaneous Integrated Boost Dose Escalation to the Gross Tumor Volume with Concurrent Chemotherapy for Stage II/III Non-Small Cell Lung Cancer - Interim Analysis International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.2416  0.373
2019 Bahig H, Gunn GB, Garden AS, Rosenthal DI, Hutcheson KA, Phan J, Fuller CD, Reddy JP, Rong Y, Zaveri J, Ng SP, Weber RS, Myers JN, Gross ND, Sturgis EM, ... Lu C, et al. Toxicity and Pharyngeal Dysphagia Outcomes from Intensity Modulated Proton Therapy for Oropharyngeal Squamous Cell Cancer International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1608  0.344
2019 Deshpande TS, Gunn GB, Fuller CD, Ye R, Rosenthal DI, Garden AS, Morrison WH, Phan J, Reddy JP, Sturgis EM, Lu C, Chambers MS, Hutcheson KA, Wang L, Zhang X, et al. Xerostomia Impacts Dysgeusia in Oropharyngeal Cancer Patients Treated with Proton Therapy International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1517  0.36
2018 Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, et al. Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer. Oncotarget. 9: 33258-33270. PMID 30279957 DOI: 10.18632/Oncotarget.25947  0.45
2018 Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, ... ... Lu C, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nature Medicine. PMID 29686424 DOI: 10.1038/S41591-018-0007-9  0.349
2018 Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, ... ... Lu C, et al. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 33: 244-258.e10. PMID 29438696 DOI: 10.1016/J.Ccell.2018.01.003  0.56
2018 Cascone T, Sepesi B, Lin HY, Kalhor N, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott F, Simon GR, Antonoff M, Mehran RJ, Rice DC, Vaporciyan AA, et al. A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 36: 8555-8555. DOI: 10.1200/Jco.2018.36.15_Suppl.8555  0.37
2018 Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach J, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel SM, Redman MW, Gandara DR, Kelly K. SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 36: 8514-8514. DOI: 10.1200/Jco.2018.36.15_Suppl.8514  0.308
2018 Wang JR, Cote GJ, Zafereo M, Iyer PC, Dadu R, Busaidy NL, Gross ND, Sturgis EM, Ferrarotto R, Lu C, Gunn GB, Myers J, Lai SY, Williams MD, Cabanillas ME. Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival. Journal of Clinical Oncology. 36: 6023-6023. DOI: 10.1200/Jco.2018.36.15_Suppl.6023  0.384
2017 Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, et al. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer: Final Results of a Phase 2 Study. Jama Oncology. e172032. PMID 28727865 DOI: 10.1001/Jamaoncol.2017.2032  0.385
2017 Reyes-Gibby CC, Melkonian SC, Wang J, Yu RK, Shelburne SA, Lu C, Gunn GB, Chambers MS, Hanna EY, Yeung SJ, Shete S. Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis. Plos One. 12: e0180396. PMID 28678827 DOI: 10.1371/Journal.Pone.0180396  0.398
2017 Cabanillas ME, Williams MD, Gunn GB, Weitzman SP, Burke L, Busaidy NL, Ying AK, Yiin YH, William WN, Lu C, Lai SY. Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head & Neck. PMID 28452157 DOI: 10.1002/Hed.24784  0.339
2017 Reyes-Gibby CC, Melkonian SC, Hanna EY, Yeung SJ, Lu C, Chambers MS, Banala SR, Gunn GB, Shete SS. Cohort study of oncologic emergencies in patients with head and neck cancer. Head & Neck. PMID 28346771 DOI: 10.1002/Hed.24748  0.328
2017 Rao SN, Zafereo M, Dadu R, Busaidy N, Hess K, Cote GJ, Williams MD, William WN, Sandulache VC, Gross ND, Gunn B, Lu C, Ferrarotto R, Lai SY, Cabanillas M. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid : Official Journal of the American Thyroid Association. PMID 28068873 DOI: 10.1089/Thy.2016.0395  0.347
2017 Eraj SA, Jomaa MK, Rock CD, Mohamed A, Garden AS, Sturgis EM, Hutcheson KA, Lu C, Frank SJ, Morrison WH, Rosenthal DI, Fuller CD, Gunn GB, Head A. Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: A symptom assessment study in patients >65 years old. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E21611  0.32
2017 William WN, Feng L, Kies MS, Ahmed S, Blumenschein GR, Glisson BS, Massarelli E, Johnson FM, Lu C, Papadimitrakopoulou V, Gold KA, Theriault RL, Heymach J, Kim ES. Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs). Journal of Clinical Oncology. 35: 6017-6017. DOI: 10.1200/Jco.2017.35.15_Suppl.6017  0.325
2017 Jassowicz A, Liu L, Huang H, Hong D, Naing A, Subbiah V, Piha-Paul S, Toung J, Vijayaraghavan R, Zhang R, Kang H, Fu S, Tsimberiodou A, Lu C, Eng C, et al. Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes Annals of Oncology. 28: v34-v35. DOI: 10.1093/Annonc/Mdx363.041  0.371
2017 Dursteler A, Kamal M, Mohamed A, Eraj S, Meheissen M, Garden A, Sturgis E, Hutcheson K, Lu C, Mendoza T, Frank S, Morrison W, Rosenthal D, Fuller C, Gunn G. Longitudinal Assessment of Chronic Fatigue in Oropharyngeal Cancer Patients After Definitive Radiation Treatment International Journal of Radiation Oncology*Biology*Physics. 99: E533. DOI: 10.1016/J.Ijrobp.2017.06.1880  0.326
2017 Nguyen Q, Blanchard P, Komaki R, Jeter M, Gomez D, Lu C, Zhu X, Gillin M, Ho J, Chang J, Hahn S, Cox J, Liao Z. Reported Outcomes and Toxicities for Inoperable, Stage II-III Non–Small Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Intensity Modulated Proton Therapy International Journal of Radiation Oncology*Biology*Physics. 99: E484-E485. DOI: 10.1016/J.Ijrobp.2017.06.1761  0.404
2017 Elhammali A, Colbert LE, Komaki RU, Lee JJ, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach J, Allen PK, Hahn SM, Cox JD, Lu C, Mohan R, Liao Z. Diffusion Capacity of the Lungs Following Passive-Scattering Proton Therapy and Intensity-Modulated Photon Radiation Therapy for Locally Advanced Non–small Cell Lung Cancer International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.1689  0.345
2017 Eraj S, Jomaa M, Rock CD, Mohamed A, Hutcheson KA, Sturgis EM, Lu C, Morrison WH, Rosenthal DI, Frank SJ, Garden A, Fuller CD, Gunn GB. Long-term patient report outcomes following radiation therapy for early stage base of tongue carcinoma: A symptom assessment study. International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.1403  0.302
2016 Pezzi TA, Mohamed AS, Sheu T, Blanchard P, Sandulache VC, Lai SY, Cabanillas ME, Williams MD, Pezzi CM, Lu C, Garden AS, Morrison WH, Rosenthal DI, Fuller CD, Gunn GB. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer. PMID 28026871 DOI: 10.1002/Cncr.30493  0.364
2016 Gellert P, Segal CV, Gao Q, López-Knowles E, Martin LA, Dodson A, Li T, Miller CA, Lu C, Mardis ER, Gillman A, Morden J, Graf M, Sidhu K, Evans A, et al. Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. Nature Communications. 7: 13294. PMID 27827358 DOI: 10.1038/Ncomms13294  0.35
2016 Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy N, Cote GJ, Singh R, Luthra R, Cabanillas M. Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma. Thyroid : Official Journal of the American Thyroid Association. PMID 27785980 DOI: 10.1089/Thy.2016.0076  0.336
2016 Pezzi TA, Mohamed AS, Sheu T, Blanchard P, Sandulache VC, Lai SY, Cabanillas ME, Williams MD, Pezzi CM, Lu C, Garden AS, Morrison WH, Rosenthal DI, Fuller CD, Gunn GB. Relationship Between Radiation Therapy Dose and Overall Survival in Anaplastic Thyroid Cancer: Analysis of the National Cancer Data Base. International Journal of Radiation Oncology, Biology, Physics. 96: E361. PMID 27674482 DOI: 10.1016/J.Ijrobp.2016.06.1538  0.369
2016 Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, Hoog J, Li T, Larson DE, Watson M, Davies SR, Hunt K, Suman VJ, Snider J, Walsh T, et al. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nature Communications. 7: 12498. PMID 27502118 DOI: 10.1038/Ncomms12498  0.337
2016 Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, Lu C, William W, Pisters K, Eapen G, Fossella F, Amin S, Bruera E. Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. Journal of Pain and Symptom Management. PMID 27330023 DOI: 10.1016/J.Jpainsymman.2015.10.023  0.369
2016 Liao ZX, Lee JJ, Komaki R, Gomez DR, O'Reilly M, Allen P, Fossella FV, Heymach J, Blumenschein GR, Choi NC, Delaney T, Hahn SM, Lu C, Cox JD, Mohan R. Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. Journal of Clinical Oncology. 34: 8500-8500. DOI: 10.1200/Jco.2016.34.15_Suppl.8500  0.391
2016 Sandulache V, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cabanillas ME. Clinical genomic testing of anaplastic thyroid carcinoma (ATC) and need for integration into future prospective clinical trials. Journal of Clinical Oncology. 34: 6085-6085. DOI: 10.1200/Jco.2016.34.15_Suppl.6085  0.303
2016 Liao Z, Lee J, Komaki R, Gomez D, O'Reilly M, Allen P, Fossella F, Heymach J, Choi N, Delaney T, Hahn S, Lu C, Cox J, Mohan R. OC-0143: A Bayesian randomisation trial of IMRT vs. PSPT for locally advanced non-small cell lung carcinoma Radiotherapy and Oncology. 119. DOI: 10.1016/S0167-8140(16)31392-5  0.342
2016 Cabanillas M, Gunn G, Williams M, Busaidy N, William W, Lu C, Lai S. Facilitating Anaplastic Specialized Treatments (FAST)—A Multidisciplinary Anaplastic Thyroid Cancer (ATC) Team International Journal of Radiation Oncology*Biology*Physics. 94: 955. DOI: 10.1016/J.Ijrobp.2015.12.306  0.303
2015 Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, Huang KL, Wyczalkowski MA, Jayasinghe R, Banerjee T, Ning J, Tripathi P, Zhang Q, Niu B, Ye K, et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications. 6: 10086. PMID 26689913 DOI: 10.1038/Ncomms10086  0.38
2015 Cabanillas ME, Dadu R, Hu MI, Lu C, Gunn GB, Grubbs EG, Lai SY, Williams MD. Thyroid Gland Malignancies. Hematology/Oncology Clinics of North America. 29: 1123-43. PMID 26568552 DOI: 10.1016/J.Hoc.2015.07.011  0.352
2015 Tang C, Lee MS, Gomez D, Levy LB, Zhuang Y, Lu C, Liao Z, Komaki R. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer. American Journal of Clinical Oncology. PMID 26165417 DOI: 10.1097/COC.0000000000000206  0.309
2015 Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, Allen PK, Mehran RJ, Lu C, Gillin M, Liao Z, Cox JD. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 115: 367-72. PMID 26028228 DOI: 10.1016/J.Radonc.2015.05.014  0.417
2015 Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1476-80. PMID 26025965 DOI: 10.1200/Jco.2013.31.15_Suppl.6067  0.349
2015 Lu C, Zhang J, Nagahawatte P, Easton J, Lee S, Liu Z, Ding L, Wyczalkowski MA, Valentine M, Navid F, Mulder H, Tatevossian RG, Dalton J, Davenport J, Yin Z, et al. The genomic landscape of childhood and adolescent melanoma. The Journal of Investigative Dermatology. 135: 816-23. PMID 25268584 DOI: 10.1038/Jid.2014.425  0.308
2015 Zhang J, McCastlain K, Qu C, Wu G, Edmonson M, Li Y, Wei L, Payne-Turner D, Yoshihara H, Churchman ML, Waanders E, Ntziachristos P, Aifantis I, Roberts KG, Ma J, ... ... Lu C, et al. Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia Blood. 126: 693-693. DOI: 10.1182/Blood.V126.23.693.693  0.311
2015 Lu C, Riedell P, Westervelt P, Miller C, Hagemann IS, Duncavage EJ, Mardis ER, Wilson RK, Ozenberger BA, Wartman LD. Abstract LB-109: Exome sequencing identifies common somatic mutations in an adult patient with a concurrent germ cell tumor (GCT) and acute myeloid leukemia (AML) suggesting a single clonal origin Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-109  0.315
2015 Jayasinghe RG, Huang K, Ning J, Wyczalkowski M, Lu C, Xie M, Wendl M, McLellan M, Ye K, Ding L. Abstract 1929: Pan-Cancer analysis of the effects of splice-altering variants on mRNA splicing and stability Cancer Research. 75: 1929-1929. DOI: 10.1158/1538-7445.Am2015-1929  0.349
2015 Liu Y, Xu T, Pang Q, Zhuang Y, Tsao A, Lu C, Komaki R, Liao Z, Gomez D. EGFR and KRAS Mutations and Disease Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 93: E435-E436. DOI: 10.1016/J.Ijrobp.2015.07.1657  0.407
2015 Yue J, Xu T, Pan T, Levy L, Gomez D, Lu C, Komaki R, Mohan R, Liao Z. The Predictive Value of Serial 18F-FDG PET/CT for Recurrence and Survival of Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy International Journal of Radiation Oncology*Biology*Physics. 93: E430-E431. DOI: 10.1016/J.Ijrobp.2015.07.1645  0.336
2014 Ding L, Kim M, Kanchi KL, Dees ND, Lu C, Griffith M, Fenstermacher D, Sung H, Miller CA, Goetz B, Wendl MC, Griffith O, Cornelius LA, Linette GP, McMichael JF, et al. Clonal architectures and driver mutations in metastatic melanomas. Plos One. 9: e111153. PMID 25393105 DOI: 10.1371/Journal.Pone.0111153  0.345
2014 Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA, Ozenberger BA, Welch JS, Link DC, Walter MJ, Mardis ER, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine. 20: 1472-8. PMID 25326804 DOI: 10.1038/Nm.3733  0.337
2014 Fagundes C, Jones D, Vichaya E, Lu C, Cleeland CS. Socioeconomic status is associated with depressive severity among patients with advanced non-small-cell lung cancer: treatment setting and minority status do not make a difference. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1459-63. PMID 25170640 DOI: 10.1097/Jto.0000000000000284  0.344
2014 Sheu T, Fuller CD, Mendoza TR, Garden AS, Morrison WH, Beadle BM, Phan J, Frank SJ, Hanna EY, Lu C, Cleeland CS, Rosenthal DI, Gunn GB. Nomogram for predicting symptom severity during radiation therapy for head and neck cancer. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 151: 619-26. PMID 25104816 DOI: 10.1177/0194599814545746  0.345
2014 Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clinical Pharmacology and Therapeutics. 96: 609-15. PMID 25054431 DOI: 10.1038/Clpt.2014.154  0.413
2014 Stewart DJ, Chang DW, Ye Y, Spitz M, Lu C, Shu X, Wampfler JA, Marks RS, Garces YI, Yang P, Wu X. Wnt signaling pathway pharmacogenetics in non-small cell lung cancer. The Pharmacogenomics Journal. 14: 509-22. PMID 24980784 DOI: 10.1038/Tpj.2014.21  0.388
2014 Pu X, Hildebrandt MA, Lu C, Roth JA, Stewart DJ, Zhao Y, Heist RS, Ye Y, Chang DW, Su L, Minna JD, Lippman SM, Spitz MR, Christiani DC, Wu X. Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clinical Pharmacology and Therapeutics. 96: 360-9. PMID 24755914 DOI: 10.1038/Clpt.2014.89  0.41
2014 Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, Lu C, Garden AS, Morrison WH, Cleeland CS, Gunn GB. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. Cancer. 120: 1975-84. PMID 24711162 DOI: 10.1002/Cncr.28672  0.325
2014 Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, Parker M, Rusch M, Nagahawatte P, Wu J, Mao S, ... ... Lu C, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Reports. 7: 104-12. PMID 24703847 DOI: 10.1016/J.Celrep.2014.03.003  0.339
2014 Sanchez-Espiridion B, Chen M, Chang JY, Lu C, Chang DW, Roth JA, Wu X, Gu J. Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. Cancer Research. 74: 2476-86. PMID 24618342 DOI: 10.1158/0008-5472.Can-13-2968  0.371
2014 McEvoy J, Nagahawatte P, Finkelstein D, Richards-Yutz J, Valentine M, Ma J, Mullighan C, Song G, Chen X, Wilson M, Brennan R, Pounds S, Becksfort J, Huether R, Lu C, et al. RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget. 5: 438-50. PMID 24509483 DOI: 10.18632/Oncotarget.1686  0.36
2014 Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, Zhang Q, Koboldt DC, Xie M, Kandoth C, McMichael JF, Wyczalkowski MA, Larson DE, Schmidt HK, Miller CA, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nature Communications. 5: 3156. PMID 24448499 DOI: 10.1038/Ncomms4156  0.589
2014 Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, Wendl MC, Ding L. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics (Oxford, England). 30: 1015-6. PMID 24371154 DOI: 10.1093/Bioinformatics/Btt755  0.305
2014 Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid : Official Journal of the American Thyroid Association. 24: 232-40. PMID 23721245 DOI: 10.1089/Thy.2013.0078  0.339
2014 Stewart DJ, Lu C, Saintigny P, Goss GD. Tumor regression as a continuous variable and survival in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 32: 8114-8114. DOI: 10.1200/Jco.2014.32.15_Suppl.8114  0.343
2014 Gunn GB, Mendoza TR, Garden AS, Wang XS, Morrison WH, Frank SJ, Beadle BM, Phan J, Fuller CD, Chambers MS, Lu C, Hanna EY, Rosenthal DI, Cleeland CS. Minocycline for reduction of patient-reported symptoms during radiation therapy for head and neck cancer: First results of a randomized trial. Journal of Clinical Oncology. 32: 6040-6040. DOI: 10.1200/Jco.2014.32.15_Suppl.6040  0.339
2014 Diaz AK, Wu G, Paugh BS, Li Y, Zhu X, Rankin S, Qu C, Chen X, Zhang J, Easton J, Edmonson M, Lu C, Nagahawatte P, Hedlund E, Rusch M, et al. Abstract PR03: The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Pr03  0.354
2014 Wang J, Lu C, Xie M, Tripathi P, McLellan M, Chen F, Johnson KJ, Ding L. Abstract 3438: Integrated analysis of germline and somatic variants in renal clear cell carcinoma Cancer Research. 74: 3438-3438. DOI: 10.1158/1538-7445.Am2014-3438  0.389
2014 Gilbertson R, Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, Lee R, Tatevossian RG, Phoenix TN, Thiruvenkatam R, White E, Tang B, Orisme W, Gupta K, ... ... Lu C, et al. C11ORF95-RELA FUSIONS DRIVE ONCOGENIC NF-KB SIGNALING IN EPENDYMOMA Neuro-Oncology. 16: iii16-iii16. DOI: 10.1093/Neuonc/Nou206.57  0.321
2013 Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, Spunt S, Valentine MB, Valentine V, Krafcik F, Lang WH, ... ... Lu C, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 24: 710-24. PMID 24332040 DOI: 10.1016/J.Ccr.2013.11.002  0.332
2013 Gibney PA, Lu C, Caudy AA, Hess DC, Botstein D. Yeast metabolic and signaling genes are required for heat-shock survival and have little overlap with the heat-induced genes. Proceedings of the National Academy of Sciences of the United States of America. 110: E4393-402. PMID 24167267 DOI: 10.1073/Pnas.1318100110  0.487
2013 Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, et al. Mutational landscape and significance across 12 major cancer types. Nature. 502: 333-9. PMID 24132290 DOI: 10.1038/Nature12634  0.363
2013 Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reports. 4: 1116-30. PMID 24055055 DOI: 10.1016/J.Celrep.2013.08.022  0.355
2013 Yuan X, Wei Q, Komaki R, Liu Z, Yang J, Tucker SL, Xu T, Heymach JV, Lu C, Cox JD, Liao Z. TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. Plos One. 8: e65659. PMID 23840350 DOI: 10.1371/Journal.Pone.0065659  0.383
2013 Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, et al. Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Research. 73: 4028-38. PMID 23704207 DOI: 10.1158/0008-5472.Can-12-4033  0.395
2013 Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop FA, Lu C, Kandoth C, Ding L, Lee R, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nature Genetics. 45: 602-12. PMID 23583981 DOI: 10.1038/Ng.2611  0.306
2013 Barney BJ, Wang XS, Lu C, Liao Z, Johnson VE, Cleeland CS, Mendoza TR. Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 22: 2143-50. PMID 23371797 DOI: 10.1007/S11136-013-0356-2  0.361
2013 Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1312-9. PMID 23300016 DOI: 10.1093/Annonc/Mds616  0.354
2013 Gunn GB, Mendoza TR, Fuller CD, Gning I, Frank SJ, Beadle BM, Hanna EY, Lu C, Cleeland CS, Rosenthal DI. High symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study. Head & Neck. 35: 1490-8. PMID 23169304 DOI: 10.1002/Hed.23181  0.34
2013 Stewart DJ, Saintigny P, Goss GD, Lu C. Survival versus intrinsic and acquired resistance in advanced non-small cell lung cancer. Journal of Clinical Oncology. 31: e19066-e19066. DOI: 10.1200/Jco.2013.31.15_Suppl.E19066  0.344
2013 Kandoth C, McLellan MD, Miller CA, Lu C, Dees N, Ye K, Niu B, Wendl MC, Wilson RK, Ding L. Abstract LB-239: Mutational and clonal analyses across TCGA cancer types using the MuSiC suite of tools. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-239  0.395
2013 Skinner HD, Pu X, Chang J, Lu C, Komaki R, Wu X. Abstract 77: Genetic variations in the stem cell pathway predict for toxicity following radiotherapy in lung cancer. Cancer Research. 73: 77-77. DOI: 10.1158/1538-7445.Am2013-77  0.432
2013 Pu X, Wang L, Hildebrandt MA, Ye Y, Chang JY, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Abstract 3626: Inflammation-related genetic variants predict radiation-induced toxicity following definitive radiotherapy for non-small cell lung cancer. Cancer Research. 73: 3626-3626. DOI: 10.1158/1538-7445.Am2013-3626  0.421
2013 Sanchez-Espiridion B, Gu J, Chang DW, Chang JY, Lu C, Roth JA, Wu X. Abstract 2554: Constitutive short telomere length and lung cancer risk: a large case- control study. Cancer Research. 73: 2554-2554. DOI: 10.1158/1538-7445.Am2013-2554  0.354
2013 Shu X, Lu C, Chang JY, Roth JA, Wu X. Abstract 1350: Genetic variations in apoptosis pathway are associated with survival in late stage non-small cell lung cancer. Cancer Research. 73: 1350-1350. DOI: 10.1158/1538-7445.Am2013-1350  0.434
2013 Nguyen Q, Komaki R, Liao Z, Allen P, Gomez D, Chang JY, Crawford C, Lu C, Tsao A, Cox JD. Risk Factors Predicting Failure and Survival in Lung Cancer Patients Treated With Definitive Dose-Escalated Proton Radiation Therapy International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.203  0.381
2012 Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, Lamprecht TL, Liu F, Xia J, Kandoth C, Fulton RS, McLellan MD, Dooling DJ, Wallis JW, ... ... Lu C, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 150: 264-78. PMID 22817890 DOI: 10.1016/J.Cell.2012.06.023  0.314
2012 Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, Chalhoub N, Baker SJ, Huether R, Kriwacki R, Curley N, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 488: 43-8. PMID 22722829 DOI: 10.1038/Nature11213  0.321
2012 Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, ... ... Lu C, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 486: 353-60. PMID 22722193 DOI: 10.1038/Nature11143  0.371
2012 Lin J, Lu C, Stewart DJ, Gu J, Huang M, Chang DW, Lippman SM, Wu X. Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk. Carcinogenesis. 33: 1699-706. PMID 22665367 DOI: 10.1093/Carcin/Bgs192  0.313
2012 Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. Plos One. 7: e34833. PMID 22558101 DOI: 10.1371/Journal.Pone.0034833  0.368
2012 Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, Cheung IY, Ding L, Fulton R, Wang J, Chen X, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. Jama. 307: 1062-71. PMID 22416102 DOI: 10.1001/Jama.2012.228  0.31
2012 Chen X, Gorlov IP, Ying J, Merriman KW, Kimmel M, Lu C, Reyes-Gibby CC, Gorlova OY. Initial medical attention on patients with early-stage non-small cell lung cancer. Plos One. 7: e32644. PMID 22412901 DOI: 10.1371/Journal.Pone.0032644  0.357
2012 Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 481: 157-63. PMID 22237106 DOI: 10.1038/Nature10725  0.327
2012 Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 481: 506-10. PMID 22237025 DOI: 10.1038/Nature10738  0.353
2012 Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, Ulyanov A, Wu G, Wilson M, Wang J, Brennan R, Rusch M, Manning AL, Ma J, Easton J, ... ... Lu C, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 481: 329-34. PMID 22237022 DOI: 10.1038/Nature10733  0.401
2012 Jiang ZQ, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, Martel MK, Vedam S, Balter P, Zhu G, Gomez D, Lu C, Mohan R, Cox JD, Liao Z. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. International Journal of Radiation Oncology, Biology, Physics. 83: 332-9. PMID 22079735 DOI: 10.1016/J.Ijrobp.2011.06.1963  0.397
2012 Robinson GW, Parker M, Kranenburg T, Lu C, Chen X, Ding L, Phoenix T, Huether R, Thiruvenkatam R, Wang J, Easton J, Onar-Thomas A, Gajjar AJ, Ellison DW, Mardis E, et al. Use of whole genome sequencing to identify novel mutations in distinct subgroups of medulloblastoma. Journal of Clinical Oncology. 30: 9518-9518. DOI: 10.1200/Jco.2012.30.15_Suppl.9518  0.335
2012 Jones D, Vichaya EG, Wang XS, Mendoza TR, Mobley GM, Lu C, Cleeland CS. Disease-driven symptoms and response to chemotherapy in treatment-naive patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30: 9118-9118. DOI: 10.1200/Jco.2012.30.15_Suppl.9118  0.385
2012 Ellis MJ, Li D, Shen D, Luo J, Suman VJ, Wallis JW, Tine BAV, Hoog J, Crowder RJ, Snider JE, Ballman K, Chen K, Koboldt DC, Schierding WS, McMichael JF, ... ... Lu C, et al. Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-423  0.35
2012 Andersson A, Ma J, Wang J, Chen X, Rusch M, Wu G, Easton J, Parker M, Raimondi S, Holmfeldt L, Becksfort J, Gupta P, Gedman A, Nakitandwe J, Payne-Turner D, ... ... Lu C, et al. Abstract 4869: Whole genome sequence analysis of MLL rearranged infant acute lymphoblastic leukemias reveals remarkably few somatic mutations: A Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project Cancer Research. 72: 4869-4869. DOI: 10.1158/1538-7445.Am2012-4869  0.335
2012 Chen X, Gorlov IP, Ying J, Merriman KW, Kimmel M, Lu C, Reyes-Gibby CC, Gorlova OY. Abstract 4449: Initial medical attention on patients with stage I or II non-small cell lung cancer Cancer Research. 72: 4449-4449. DOI: 10.1158/1538-7445.Am2012-4449  0.345
2012 Wang H, Gomez D, Komaki R, Welsh J, O'Reilly M, Chang J, Zhuang Y, Levy L, Lu C, Liao Z. Improved Survival Outcomes in Non-small Cell Lung Cancer Patients With Incidental Concurrent Use of Beta-Blockers and Definitive Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 84: S587. DOI: 10.1016/J.Ijrobp.2012.07.1566  0.39
2011 Sosa JA, Elisei R, Jarzab B, Bal CS, Koussis H, Gramza AW, Ben-Yosef R, Gitlitz BJ, Haugen B, Karandikar SM, Khuri FR, Licitra LF, Remick SC, Marur S, Lu C, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5502. PMID 28021454 DOI: 10.1200/Jco.2011.29.15_Suppl.5502  0.368
2011 Gunn GB, Mendoza TR, Garden AS, Wang XS, Morrison WH, Frank SJ, Hanna EY, Lu C, Beadle BM, Ang KK, Cleeland CS, Rosenthal DI. Patient-reported fatigue in head and neck cancer survivors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5523. PMID 28021390 DOI: 10.1200/Jco.2011.29.15_Suppl.5523  0.325
2011 William Junior WN, Weber RS, Lee JJ, Myers J, Ginsberg LE, El-Naggar AK, Sturgis EM, Sabichi AL, Kies MS, Hanna EY, Hessel AC, Lu C, Lai SY, Ayuste R, Lippman SM, et al. Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5520. PMID 28021383 DOI: 10.1200/Jco.2011.29.15_Suppl.5520  0.316
2011 Yin J, Lu C, Gu J, Lippman SM, Hildebrandt MA, Lin J, Stewart D, Spitz MR, Wu X. Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis. 32: 1867-71. PMID 21965272 DOI: 10.1093/Carcin/Bgr217  0.406
2011 Dai J, Gu J, Lu C, Lin J, Stewart D, Chang D, Roth JA, Wu X. Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. Plos One. 6: e21120. PMID 21698121 DOI: 10.1371/Journal.Pone.0021120  0.375
2011 Lin M, Stewart DJ, Spitz MR, Hildebrandt MA, Lu C, Lin J, Gu J, Huang M, Lippman SM, Wu X. Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis. 32: 1050-6. PMID 21515830 DOI: 10.1093/Carcin/Bgr067  0.412
2011 Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, ... Lu C, et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. Journal of the National Cancer Institute. 103: 817-25. PMID 21483023 DOI: 10.1093/Jnci/Djr075  0.44
2011 Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 117: 4707-13. PMID 21437893 DOI: 10.1002/cncr.26080  0.402
2011 Mendoza TR, Wang XS, Lu C, Palos GR, Liao Z, Mobley GM, Kapoor S, Cleeland CS. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. The Oncologist. 16: 217-27. PMID 21285393 DOI: 10.1634/Theoncologist.2010-0193  0.364
2011 Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 117: 3004-13. PMID 21264827 DOI: 10.1002/Cncr.25848  0.39
2011 Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer (Amsterdam, Netherlands). 71: 82-8. PMID 20447721 DOI: 10.1016/J.Lungcan.2010.04.008  0.41
2011 Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Investigational New Drugs. 29: 499-505. PMID 20094773 DOI: 10.1007/S10637-009-9380-Z  0.344
2011 Andersson AK, Ma J, Wang J, Chen X, Rusch M, Wu G, Easton J, Parker M, Raimondi SC, Holmfeldt L, Gedman AL, Song G, Becksfort J, Gupta P, Ulyanov A, ... ... Lu C, et al. Whole Genome Sequence Analysis of 22 MLL Rearranged Infant Acute Lymphoblastic Leukemias Reveals Remarkably Few Somatic Mutations: A Report From the St Jude Children‘s Research Hospital - Washington University Pediatric Cancer Genome Project Blood. 118: 69-69. DOI: 10.1182/Blood.V118.21.69.69  0.329
2011 Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen S, Collins-Underwood R, Ma J, Roberts KG, et al. Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project Blood. 118: 68-68. DOI: 10.1182/Blood.V118.21.68.68  0.355
2011 Stewart DJ, Chang DW, Ye Y, Spitz MR, Lu C, Wu X. Abstract 5475: Wnt pathway pharmacogenetics in lung cancer patients treated with platinum regimens Cancer Research. 71: 5475-5475. DOI: 10.1158/1538-7445.Am2011-5475  0.405
2011 Lu C, Stewart DJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Lee JJ, McMannis JD, Templeton NS, Roth JA. Abstract 5391: Systemic gene therapy with tumor suppressor TUSC2/FUS1 nanoparticles for recurrent/metastatic lung cancer Cancer Research. 71: 5391-5391. DOI: 10.1158/1538-7445.Am2011-5391  0.442
2011 Pu X, Spitz MR, Amos C, Ye Y, Hildebrandt MA, Chang D, Lu C, Stewart D, Roth JA, Lippman SM, Christiani D, Wu X. Abstract 4662: Genetic predictors of clinical outcomes for patients with non-small cell lung cancer Cancer Research. 71: 4662-4662. DOI: 10.1158/1538-7445.Am2011-4662  0.417
2011 Fang L, Chang JY, Komaki R, Liao Z, Kim E, Allen P, Lu C, Tsao A, Gillin M, Cox JD. Failure Patterns and Toxicity After Chemoradiation with 74 Gy(RBE) for Non-small Cell Lung Cancer International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.1130  0.368
2010 Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. Plos One. 5: e12402. PMID 20811626 DOI: 10.1371/Journal.Pone.0012402  0.344
2010 Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. The New England Journal of Medicine. 363: 24-35. PMID 20530316 DOI: 10.1056/Nejmoa0912217  0.342
2010 Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. Journal of the National Cancer Institute. 102: 859-65. PMID 20505152 DOI: 10.1093/Jnci/Djq179  0.397
2010 Wang XS, Shi Q, Lu C, Basch EM, Johnson VE, Mendoza TR, Mobley GM, Cleeland CS. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 116: 137-45. PMID 19852033 DOI: 10.1002/Cncr.24703  0.414
2010 Sabichi AL, Kies MS, Glisson BS, Lu C, Ginsberg LE, Bartos CI, Feng L, Tran HT, Lippman SM, Blumenschein GR. A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). Journal of Clinical Oncology. 28: 5532-5532. DOI: 10.1200/Jco.2012.30.15_Suppl.5592  0.36
2010 Cleeland CS, Mendoza TR, Palos GR, Lu C, Nazario LA, Lynch GR, Mobley GM, Wang XS. Factors contributing to high symptom burden during chemotherapy for advanced lung cancer: The risk of being underserved. Journal of Clinical Oncology. 28: 9003-9003. DOI: 10.1200/Jco.2010.28.15_Suppl.9003  0.422
2010 Lu C, Stewart DJ, Ji L, Ramesh R, Jayachandran G, Erasmus JJ, Lee J, Templeton NS, McMannis JD, Roth JA. Systemic gene therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. Journal of Clinical Oncology. 28: 7582-7582. DOI: 10.1200/Jco.2010.28.15_Suppl.7582  0.428
2010 Ang K, Zhang Q, Wheeler RH, Rosenthal DI, Nguyen-Tan F, Kim H, Lu C, Axelrod RS, Silverman CI, Weber RS. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome. Journal of Clinical Oncology. 28: 5507-5507. DOI: 10.1200/Jco.2010.28.15_Suppl.5507  0.357
2010 Pu X, Lu C, Stewart DJ, Gu J, Hildebrandt MAT, Lin J, Lippman SM, Wu X. Abstract A3: MicroRNA‐related polymorphisms are associated with clinical outcomes in early stage non‐small cell lung cancer patients Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-A3  0.35
2010 Yin J, Wu X, Lu C, Chang J, Hildebrandt M, Stewart D, Spitz MR, Gu J. Abstract 4662: Genetic variations in the cell-cycle pathway and survival of patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy Cancer Research. 70: 4662-4662. DOI: 10.1158/1538-7445.Am10-4662  0.426
2010 Lin M, Hildebrandt M, Stewart D, Lippman SM, Lu C, Spitz MR, Wu X. Abstract 1675: Lung cancer chemotherapy: genetic variations in the transforming growth factor beta pathway as predictors of survival Cancer Research. 70: 1675-1675. DOI: 10.1158/1538-7445.Am10-1675  0.408
2010 Jiang Z, Zhuang Y, Komaki R, Jeter M, O'Reilly M, Gomez D, Lin SH, Lu C, Blumenschein G, Liao Z. Prognostic Factors for Clinical Outcomes and Treatment-related Late Toxicities of Inoperable Non-small Cell Lung Cancer (NSCLC) after Definitive Intensity Modulated Radiotherapy (IMRT) International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.1212  0.394
2010 Mendoza T, Gunn G, Wang X, Frank S, Beadle B, Shah S, Lu C, Hanna E, Cleeland C, Rosenthal D. Impact of Symptom Burden on Survival in Patients with Head and Neck Cancer Treated with Definitive Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 78: S470-S471. DOI: 10.1016/J.Ijrobp.2010.07.1103  0.365
2010 Rosenthal D, Mendoza T, Gunn G, Wang X, Hanna E, Lu C, Garden A, Morrison W, Ang K, Cleeland C. Symptom Burden during Radiation Therapy and Chemoradiation for Head and Neck Cancer International Journal of Radiation Oncology*Biology*Physics. 78: S457. DOI: 10.1016/J.Ijrobp.2010.07.1072  0.322
2009 Lu C, Stewart DJ, Ji L, Ramesh R, Jayachandran G, Erasmus J, Lee JJ, Templeton NS, McMannis JD, Roth JA. A phase I trial of intravenous therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e19065. PMID 27962142 DOI: 10.1200/Jco.2009.27.15_Suppl.E19065  0.404
2009 Airoldi EM, Huttenhower C, Gresham D, Lu C, Caudy AA, Dunham MJ, Broach JR, Botstein D, Troyanskaya OG. Predicting cellular growth from gene expression signatures. Plos Computational Biology. 5: e1000257. PMID 19119411 DOI: 10.1371/Journal.Pcbi.1000257  0.7
2009 Lu C, Brauer MJ, Botstein D. Slow growth induces heat-shock resistance in normal and respiratory-deficient yeast. Molecular Biology of the Cell. 20: 891-903. PMID 19056679 DOI: 10.1091/Mbc.E08-08-0852  0.471
2009 Chang J, Komaki R, Bucci M, Lu C, Wen H, DeGracia B, Gillin M, Mohan R, Cox J. Failure Patterns and Toxicity of Concurrent Proton Therapy and Chemotherapy for Stage III Non–small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 75: S446-S447. DOI: 10.1016/J.Ijrobp.2009.07.1021  0.385
2008 Lu C, Ye Y, Clague J, Chang JY, Lippman SM, Stewart DJ, Spitz M, Wu X. Associations between genetic polymorphisms and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with paclitaxel-based therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11107. PMID 27947885 DOI: 10.1200/Jco.2008.26.15_Suppl.11107  0.41
2008 Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, Gu J, Hong WK, Stewart D, Spitz MR. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenetics and Genomics. 18: 955-65. PMID 18854777 DOI: 10.1097/Fpc.0B013E32830Efdd4  0.39
2008 Xing J, Stewart DJ, Gu J, Lu C, Spitz MR, Wu X. Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer British Journal of Cancer. 98: 1716-1722. PMID 18414412 DOI: 10.1038/Sj.Bjc.6604343  0.417
2008 Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Investigational New Drugs. 26: 81-7. PMID 17960324 DOI: 10.1007/S10637-007-9075-2  0.39
2007 Wang W, Spitz MR, Yang H, Lu C, Stewart DJ, Wu X. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5974-81. PMID 17908995 DOI: 10.1158/1078-0432.Ccr-07-0113  0.387
2007 Heinicke S, Livstone MS, Lu C, Oughtred R, Kang F, Angiuoli SV, White O, Botstein D, Dolinski K. The Princeton Protein Orthology Database (P-POD): a comparative genomics analysis tool for biologists. Plos One. 2: e766. PMID 17712414 DOI: 10.1371/Journal.Pone.0000766  0.467
2007 Xing J, Spitz MR, Lu C, Zhao H, Yang H, Wang W, Stewart DJ, Wu X. Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 1517-22. PMID 17627019 DOI: 10.1158/1055-9965.Epi-07-0111  0.312
2007 Yang H, Spitz MR, Stewart DJ, Lu C, Gorlov IP, Wu X. ATM sequence variants associate with susceptibility to non-small cell lung cancer. International Journal of Cancer. Journal International Du Cancer. 121: 2254-9. PMID 17582598 DOI: 10.1002/Ijc.22918  0.407
2007 Gu J, Gong Y, Huang M, Lu C, Spitz MR, Wu X. Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis. 28: 350-5. PMID 16926177 DOI: 10.1093/Carcin/Bgl149  0.363
2007 Lu C, Lee JJ, Komaki R, Herbst RS, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong M, Fisch MJ. A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC) (NCI T99–0046, RTOG 02–70, MDA 99–303) Journal of Clinical Oncology. 25: 7527-7527. DOI: 10.1200/Jco.2007.25.18_Suppl.7527  0.345
2007 Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, Chen H, Stadler WM, Vokes EE. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM) Journal of Clinical Oncology. 25: 7526-7526. DOI: 10.1200/Jco.2007.25.18_Suppl.7526  0.314
2007 Cleeland CS, Shi Q, Lu C, Johenson V, Mendoza T, Palos L, Mobley G, Wang X. Palliative chemotherapy and cancer-related fatigue in advanced NSCLC patients Journal of Clinical Oncology. 25: 6622-6622. DOI: 10.1200/Jco.2007.25.18_Suppl.6622  0.417
2007 Wang XS, Lu C, Shi Q, Fariclough D, Mobley G, Palos L, Mendoza T, Cleeland C. Symptom burden and survival outcome: 3 cycles versus 6 cycles of chemotherapy in advanced NSCLC Journal of Clinical Oncology. 25: 17054-17054. DOI: 10.1200/Jco.2007.25.18_Suppl.17054  0.34
2007 Zinner RG, Fossella FV, Kies M, Herbst RS, Lu C, Johnson F, Price J, Cleeland C, Wang S. P3-164: A phase II trial of pemetrexed(p) in patients (pts) with performance status (PS) 2 and 3 as 1st– and 2nd– line treatment for advanced non–small–cell lung cancer (NSCLC) Journal of Thoracic Oncology. 2: S749. DOI: 10.1097/01.Jto.0000284139.01895.99  0.374
2007 Lu C, Spitz MR, Yang H, Wang W, Stewart DJ, Wu X. C8-04: Genetic polymorphisms in cell cycle control pathways and lung cancer risk Journal of Thoracic Oncology. 2: S384. DOI: 10.1097/01.Jto.0000283239.29701.1E  0.348
2007 Ang K, Pajak T, Rosenthal D, Nguyen F, Lu C, Kim H, Axelrod R, List M, Silverman C, Weber R. A Phase III Trial to Compare Standard Versus Accelerated Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Compliance and Toxicity International Journal of Radiation Oncology*Biology*Physics. 69: S12-S13. DOI: 10.1016/J.Ijrobp.2007.07.023  0.324
2006 Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7329-38. PMID 17189404 DOI: 10.1158/1078-0432.Ccr-06-0894  0.427
2006 Lin X, Gu J, Lu C, Spitz MR, Wu X. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5720-5. PMID 17020976 DOI: 10.1158/1078-0432.Ccr-05-2809  0.379
2006 Lu C, Wistuba I, Zhou X, Bekele BN, Putnam JB, Correa A, Mao L. Prognostic role of promoter hypermethylation of death-associated protein (DAP) kinase and p16 genes in early-stage non-small cell lung cancer Journal of Clinical Oncology. 24: 7216-7216. DOI: 10.1200/Jco.2006.24.18_Suppl.7216  0.341
2006 Kies MS, Garden AS, Holsinger C, Papadimitrakopoulou V, El-Naggar AK, Gillaspy K, Lewin J, Lu C, Villalobos S, Glisson BS. Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN) Journal of Clinical Oncology. 24: 5520-5520. DOI: 10.1200/Jco.2006.24.18_Suppl.5520  0.315
2006 Rohatgi PR, Chang JY, Spitz MR, Liu J, Lu C, Stewart D, Allen PK, Cox JD, Komaki R, Wu X. 1045 : p53 Polymorphisms Predict Poor Clinical Outcome in Non-Small-Cell Lung Cancer Patients Treated With Radiotherapy/Chemotherapy International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.310  0.421
2005 Heymach JV, Johnson BE, Rowbottom JA, Fidias P, Lu C, Prager D, Roubec J, Csada E, Dimery I, Herbst RS. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3023. PMID 27945771 DOI: 10.1200/Jco.2005.23.16_Suppl.3023  0.337
2005 Komaki R, Allen P, Glisson B, Lu C, Fossella F, Liao Z, Jeter M, Stevens C, Chang J, Guerrero T, Blumenschein G. Hyperfractionated/accelerated thoracic radiation therapy (HFXRT) increased survival compared to daily RT (QDRT) for limited small cell lung cancer (LSCLC) with Concurrent Chemotherapy (ChT). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7158. PMID 27944978 DOI: 10.1200/Jco.2005.23.16_Suppl.7158  0.403
2005 Lu C, Komaki R, Herbst RS, Evans WK, Lee JJ, Truong M, Moore CA, Choy H, Bleyer A, Fisch MJ. A phase III study of Æ-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell Lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim report of toxicity and response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7144. PMID 27944961 DOI: 10.1200/Jco.2005.23.16_Suppl.7144  0.359
2005 Ji L, Kawashima H, Lu C, Kurie J, Chada S, Minna JD, Roth JA. Synergistic inhibition of EGFR tyrosine kinase and tumor cell growth in non-small cell lung cancer (NSCLC) by combination treatment with FUS1-nanoparticles and gefitinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7081. PMID 27944549 DOI: 10.1200/Jco.2005.23.16_Suppl.7081  0.366
2005 Wu X, Lu C, Chiang SS, Ajani JA. Pharmacogenetics in esophageal cancer. Seminars in Oncology. 32: S87-9. PMID 16399440 DOI: 10.1053/J.Seminoncol.2005.04.031  0.428
2005 Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2894-8. PMID 15837739 DOI: 10.1158/1078-0432.Ccr-04-2176  0.409
2005 Schabath MB, Delclos GL, Martynowicz MM, Greisinger AJ, Lu C, Wu X, Spitz MR. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. American Journal of Epidemiology. 161: 412-22. PMID 15718477 DOI: 10.1093/Aje/Kwi063  0.343
2004 Lu C, Zhao H, Truong M, Dong Q, Spitz MR, Wu X. Association between glutathione S-transferase (GST) P1 polymorphisms and survival of patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7009. PMID 28016281 DOI: 10.1200/Jco.2004.22.14_Suppl.7009  0.309
2004 Tran HT, Zinner R, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum B, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2050. PMID 28015661 DOI: 10.1200/Jco.2004.22.90140.2050  0.353
2004 Heymach JV, Dong RP, Dimery I, Wheeler C, Fidias P, Lu C, Johnson B, Herbst R. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3051. PMID 28015208 DOI: 10.1200/Jco.2004.22.14_Suppl.3051  0.328
2004 Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, Hong WK, Mao L. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6119-25. PMID 15447998 DOI: 10.1158/1078-0432.CCR-04-0652  0.321
2004 Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 54: 308-14. PMID 15184994 DOI: 10.1007/S00280-004-0816-Z  0.316
2004 Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. International Journal of Radiation Oncology, Biology, Physics. 58: 1369-77. PMID 15050312 DOI: 10.1016/J.Ijrobp.2003.10.005  0.411
2004 Blumenschein G, Lu C, Kies M, Glisson B, Papadimitrakopoulou V, Zinner R, Kim E, Gillenwater A, Chiao J, Hong W. Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer(SCCHN) Journal of Clinical Oncology. 22: 5578-5578. DOI: 10.1200/Jco.2004.22.90140.5578  0.364
2004 Chang JY, Wu X, Komaki R, Sasaki R, Allen P, Liao Z, Stevens CW, Lu C, Fossella FV, Cox JD, Spitz MR. Mutagen sensitivity predicts poor overall and disease specific survival in patients with stage III non-small cell lung cancer treated with chemo/radiotherapy International Journal of Radiation Oncology Biology Physics. 60. DOI: 10.1016/J.Ijrobp.2004.06.200  0.42
2003 Herbst RS, Khuri FR, Lu C. Erratum: The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma (Cancer (2002) 95 (340-353)) Cancer. 97. DOI: 10.1002/Cncr.11301  0.393
2002 Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 95: 340-53. PMID 12124835 DOI: 10.1002/Cncr.10629  0.4
2001 Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK, Herbst RS. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer Lung Cancer. 34: 427-432. PMID 11714540 DOI: 10.1016/S0169-5002(01)00278-1  0.411
2000 Herbst R, Khuri F, Jung M, Fossella F, Lee J, Glisson B, Shin D, Pisters K, Papadimitrakopoulou V, Kurie J, Perez-Soler R, Liu D, Lu C, Guerra M, Munden R, et al. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer Lung Cancer. 29: 12. DOI: 10.1016/S0169-5002(00)80033-1  0.411
Show low-probability matches.